Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.59 |
| ▸ | NPY1R | P25929 | 9/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.59 |
| ▸ | NPY2R | P49146 | 5/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9755306 | 0.93 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL9755301 | 0.93 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29649760 | 0.92 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29649734 | 0.92 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29611423 | 0.92 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL7353834 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29779431 | 0.90 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29580583 | 0.90 | VIPR2 (0.56) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7350041 | 0.89 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31195744 | 0.89 | KISS1R (0.59) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022094025-A1 | ANGIOTENSIN-1-7 FOR THE TREATMENT OF COVID-19 | DIZEREGA GERE (US) | 2022-05-05 | — | — | WO | claimed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-119574244-A | Human angiotensin II purity standard substance and preparation method and application thereof | 广东省计量科学研究院（华南国家计量测试中心） | 2025-03-07 | — | — | CN | disclosed |
| EP-4371556-A1 | ANGIOTENSIN(1-7) PHARMACEUTICAL COMPOSITIONS FOR INHALATION | Explicat Pharma GmbH (DE) | 2024-05-22 | — | — | EP | disclosed |
| US-20220243210-A1 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | disclosed |
| WO-2022094025-A1 | ANGIOTENSIN-1-7 FOR THE TREATMENT OF COVID-19 | DIZEREGA GERE (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | NPY4R 295/4885NPY1R 176/4885NPY5R 334/4885 |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | NPY4R 295/4885NPY1R 176/4885NPY5R 334/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | NPY4R 1830/4885NPY1R 504/4885NPY5R 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.